Universitätsklinikum Ulm

Running trials

• Recruiting

  Registry for Duchenne and Becker Muscular Dystrophy

  NCT07402122· Source

• Recruiting

  A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG

  NCT06792994· Source

• Recruiting

  Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients

  NCT07176312· Phase 2· Source

• Recruiting

  Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment

  NCT07281833· Phase 3· Source

• Recruiting

  - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

  NCT06856837· Phase 2· Source

• Recruiting

  Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study

  NCT07264426· Source

• Recruiting

  Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake

  NCT06571149· Phase 4· Source

• Active, not recruiting

  Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

  NCT06625320· Phase 3· Source

• Active, not recruiting

  A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

  NCT06598943· Phase 2· Source

• Recruiting

  Intracoronary Stenting and Additional Results Achieved by ShockWAVE Coronary Lithotripsy

  NCT06369142· Source

• Recruiting

  Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

  NCT06324357· Phase 1/2· Source

• Active, not recruiting

  S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP

  NCT06188702· Phase 1/2· Source

• Active, not recruiting

  A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

  NCT05936359· Phase 1· Source

• Recruiting

  Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO-EU Trial

  NCT05496998· Source

• Active, not recruiting

  TRICuspid Intervention in Heart Failure Trial

  NCT04634266· Source

• Active, not recruiting

  Prognostic Role of Circulating Tumor DNA in Resectable Pancreatic Cancer

  NCT04246203· Source

• Active, not recruiting

  A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab

  NCT07280377· Phase 1/2· Source

• Active, not recruiting

  A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

  NCT05050942· Phase 3· Source

• Active, not recruiting

  A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab

  NCT04770896· Phase 3· Source

• Active, not recruiting

  Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

  NCT04603495· Phase 3· Source

• Active, not recruiting

  Restoration of Central Vision With the PRIMA System in Patients With Atrophic AMD

  NCT04676854· Source

• Active, not recruiting

  Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

  NCT04595565· Phase 3· Source

• Active, not recruiting

  Intensive Rhythm Monitoring to Decrease Ischemic Stroke and Systemic Embolism - the Find-AF 2 Study

  NCT04371055· Source

• Recruiting

  High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

  NCT04221035· Phase 3· Source

• Active, not recruiting

  Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics

  NCT03897127· Phase 3· Source

• Active, not recruiting

  Automatic PredICtion of Edema After Stroke

  NCT04057690· Source

• Recruiting

  PACAREG: a Multicenter Registry Trial in Pancreatic Ductal Adencarcinoma

  NCT04099134· Source

• Active, not recruiting

  International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer

  NCT03386734· Source

• Active, not recruiting

  Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

  NCT03049189· Phase 3· Source

• Active, not recruiting

  A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

  NCT02711553· Phase 2· Source

• Active, not recruiting

  Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

  NCT02632708· Phase 1· Source

• Active, not recruiting

  A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

  NCT02246621· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer2 recruiting
• Gastric and esophageal cancer2 recruiting
• Metastatic breast cancer2 recruiting
• Childhood cancers1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Coronary artery disease1 recruiting
• Duchenne muscular dystrophy1 recruiting
• Neuroblastoma1 recruiting
• Pancreatic cancer1 recruiting
• Stroke1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers

  NCT06667414· Source

• Completed

  Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)

  NCT06182085· Phase 2· Source

• Withdrawn

  Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

  NCT05743270· Phase 2· Source

• Terminated

  IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack

  NCT06139328· Phase 2· Source

• Completed

  Safety and Efficacy of the Olympus CADe System in Real-time Colonoscopy

  NCT05943288· Source

• Completed

  A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

  NCT05805501· Phase 2· Source

• Completed

  Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

  NCT05804032· Phase 3· Source

• Completed

  A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906

  NCT05296733· Phase 1· Source

• Recruiting

  A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

  NCT05091424· Phase 1· Source

• Terminated

  The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis

  NCT04985968· Phase 3· Source

• Completed

  A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

  NCT04771273· Phase 2· Source

• Completed

  Combined Active Treatment in Type 2 Diabetes With NASH

  NCT04639414· Phase 4· Source

• Completed

  A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease

  NCT04592874· Phase 2· Source

• Completed

  Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment

  NCT04511455· Phase 2· Source

• Terminated

  Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker

  NCT04633148· Phase 1· Source

• Completed

  Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease

  NCT04462276· Phase 2· Source

• Terminated

  A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment

  NCT04338269· Phase 3· Source

• Completed

  Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer

  NCT04257448· Phase 1/2· Source

• Completed

  BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients

  NCT03944356· Source

• Completed

  PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation

  NCT03996772· Phase 3· Source

• Completed

  A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

  NCT03900598· Phase 1· Source

• Completed

  EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

  NCT03594110· Phase 3· Source

• Completed

  A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

  NCT03535740· Phase 2· Source

• Completed

  RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients

  NCT03520946· Phase 3· Source

• Completed

  Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer

  NCT03647969· Phase 2· Source

• Terminated

  Spironolactone in the Treatment of Heart Failure

  NCT04727073· Phase 3· Source

• Completed

  Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC

  NCT03426657· Phase 2· Source

• Completed

  Treatment of Older Patients With B-precursor ALL With Sequential Dose Reduced Chemotherapy and Blinatumomab

  NCT03480438· Phase 2· Source

• Completed

  Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)

  NCT03377491· Phase 3· Source

• Completed

  A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

  NCT03467373· Phase 1· Source

• Completed

  A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

  NCT03283085· Phase 3· Source

• Completed

  Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer

  NCT03044587· Phase 2· Source

• Completed

  A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors

  NCT03267316· Phase 1/2· Source

• Completed

  Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy

  NCT03081143· Phase 2/3· Source

• Completed

  Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality

  NCT03036462· Phase 4· Source

• Completed

  Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria

  NCT03157635· Phase 1/2· Source

• Completed

  ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab

  NCT02891824· Phase 3· Source

• Completed

  A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer

  NCT02747004· Phase 2· Source

• Completed

  Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses

  NCT02467270· Phase 2· Source

• Completed

  R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL

  NCT01865110· Phase 3· Source

• Completed

  Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

  NCT01909453· Phase 3· Source